We Are Apellis We understand that living with a serious disease–like PNH–can pose many challenges and needs that can remain unaddressed. As leaders in developing targeted C3 therapies, we aim to address these needs by leveraging courageous science, creativity, and compassion to develop transformative therapies for a broad range of debilitating diseases that are driven…
Blue Earth Diagnostics is an established molecular imaging company focused on providing innovative, well-differentiated diagnostics solutions, informing patient management, and driving future therapies in cancer. Formed in 2014, Blue Earth Diagnostics’ success is driven by our management expertise and agility, supported by our demonstrated track record of rapid development and commercialization of PET radiopharmaceuticals. Blue…
About Blueprint Medicines Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and…
Deciphera Pharmaceuticals Deciphera Pharmaceuticals is focused on discovering, developing, and bringing important new medicines to patients for the treatment of cancer. Enabled by our proprietary kinase switch control inhibitor platform, our drug candidates are designed to stop cancers from growing and spreading by inhibiting mutant forms or over expression of a family of enzymes…
Epizyme’s vision is to rewrite treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme aspires to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action. Learn more Epizyme.com. Patient Assistance & Product Support: EpizymeNOW 1-833-4EPI(NOW) (437-4669)
Rigel Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company focused on discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Rigel’s clinical development programs span multiple disease targets including chronic immune thrombocytopenia, autoimmune hemolytic anemia and others. Rigel’s first FDA approved product…
Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier’s global portfolio…
The importance of ONE package. As part of AmerisourceBergen, Oncology Supply meticulously distributes chemotherapy, immunotherapy and supportive care products to community oncology practices nationwide from our office and distribution center in Dothan, Alabama. As your trusted supplier and solutions partner, we go beyond the product, delivering the key knowledge that creates opportunities for growth, solutions…
The STAR (Spectrum Therapy Access Resources) Co-pay Program will provide the following co-pay assistance to eligible patients, across the Spectrum portfolio: First Date of Service: Patient will have a $0 patient out of pocket. STAR will cover 100% of the co-insurance/ cost share for the Spectrum product. Subsequent Dates of Service: Patient will be responsible…
Ipsen Biopharmaceuticals and its research and development team are part of an innovation-driven international specialty pharmaceutical group (the Ipsen Group), with global headquarters in Paris and US headquarters in Basking Ridge, NJ (commercial/marketing), and Massachusetts (research and development). The global company markets more than 20 drugs and employs nearly 4,600 people around the world. Ipsen…
© 2021 FLASCO | Premium Website Design by The HDG
